Skip to main content
Equibles
ICCC logo

ICCC · Immucell Corp /De/ · Metrics

Track ICCC — free

Use ICCC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ICCC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.85 -0.07 (-0.66%) At close · Sep 11
Rebalance outlook locked
Market Cap
$89.46M
Shares
9.08M

ICCC metrics

81 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.85
Market cap
$89.46M

Price action

20 metrics
Price change (1W)
-0.9%
Price change (30D)
-9.0%
Price change (3M)
+1.8%
Price change (6M)
+49.5%
Price change (YTD)
+61.2%
Price change (1Y)
+61.0%
Trailing year
Price change (5Y)
+7.2%
52-week high
$11.72
52-week low
$4.56
Change from 52-week high
-15.4%
Change from 52-week low
+117.4%
Annualized volatility
51.4%
Annualized volatility (3M)
45.7%
Beta
0.4
RSI (14D)
42.4
Price vs SMA 50
-6.3%
Price vs SMA 200
+22.5%
Avg volume (3M)
28,369
Relative volume
0.4
Average dollar volume
$295,055

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
9.08M

Valuation

12 metrics
P / E (TTM)
141.6
Trailing earnings · reciprocal yield 0.7%
PEG ratio
0.6
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.9×
reciprocal yield 34.1%
P / book
2.9
reciprocal yield 34.8%
FCF yield
4.7%
TTM · current market cap
Buyback yield
—
P / FCF
21.4
reciprocal yield 4.7%
P / operating cash flow
15.3
reciprocal yield 6.5%
Earnings yield
0.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
355.8×
reciprocal yield 0.3%
EV / revenue historical average (3Y)
2.5×
reciprocal yield 40.7%
EV / revenue historical average (5Y)
2.7×
reciprocal yield 37.7%
EV / EBIT historical average (3Y)
31.5×
reciprocal yield 3.2%
EV / EBIT historical average (5Y)
69.7×
reciprocal yield 1.4%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
40.3%
Operating margin
12.6%
Trailing 12 months
Net margin
2.6%
Gross profit (TTM)
$12.37M
Operating profit (TTM)
$3.87M
Net income (TTM)
$787,373
Trailing 12 months
Diluted EPS (TTM)
$0.07
FCF margin
13.7%
Effective tax rate
7.8%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.99

Growth

11 metrics
Revenue growth YoY
+11.5%
Year over year
Net income growth YoY
+265.6%
Revenue (TTM)
$30.68M
Trailing 12 months
EPS growth YoY
+233.3%
Shares change YoY
+1.7%
Year over year · more shares
Revenue CAGR (3Y)
+14.2%
Revenue CAGR (5Y)
+12.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
2.5%
Return on assets
1.7%
Debt / equity
0.3
Current ratio
4.8
EBITDA (TTM)
$6.29M
Free cash flow (TTM)
$4.21M
Quick ratio
2.7
Interest coverage
8.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$8.86M
Total assets
$46.63M
Total debt
$8.30M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$5.89M
Capital expenditures (TTM)
$1.68M
R&D (TTM)
$1.89M
SG&A (TTM)
—
Stock compensation (TTM)
$554,758
R&D / revenue
6.2%
Stock compensation / revenue
1.8%

Ownership (13F)

3 metrics
13F filers
31
13F filer change QoQ
+4
Institutional ownership
14.7%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
33 / 100

Insider activity

2 metrics
Net insider buying (90D)
$75,960
Insider-sentiment score
81 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 811641 CUSIP 452525306 13F (30d) 9 filings 9 filers Visit website Investor relations